

https://doi.org/10.15407/dopovidi2022.03.087 UDC 616.379-008.64:616.12:616.98

M.D. Tronko, https://orcid.org/0000-0001-7421-0981

V.V. Pushkarev, https://orcid.org/0000-0001-5940-5510

L.K. Sokolova, https://orcid.org/0000-0003-0011-0106

S.A. Cherviakova, https://orcid.org/0000-0002-6917-5736

Y.B. Belchina, https://orcid.org/0000-0002-4289-8977

O.I. Kovzun, https://orcid.org/0000-0001-8164-7671

B.B. Guda, https://orcid.org/0000-0002-9181-0679

V.M. Pushkarev, https://orcid.org/0000-0003-0347-7771

V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kyiv E-mail: pushkarev.vm@gmail.com

Effects of COVID-19 and diabetes mellitus on AMPKα1 and IRS-1 amount in the blood plasma of patients

Presented by Corresponding Member of the NAS of Ukraine M.D. Tronko

The aim of the study was to determine the levels of AMPK α 1 and IRS-1 in the blood of patients with diabetes mellitus and COVID-19. AMPK α 1 and IRS-1 were determined using enzyme-linked immunosorbent assay (ELISA) (Elabscience, USA). AMPK controls the energy balance of the cell, stimulates catabolic processes – absorption of glucose, fatty acids, and their conversion by mitochondrial oxidation and glycolysis. With type 2 diabetes and obesity, its activity decreases, and the activity of protein kinases mTORC1/p70S6K increases, leading to phosphorylation of insulin receptor substrate-1 (IRS) and insulin resistance. The level of AMPK α 1 in the blood of diabetic patients was significantly higher than in the blood of healthy people. The amount of AMPK α 1 in the blood of people recovered from COVID-19 demonstrated the further growth of AMPK α 1. The level of AMPK α 1 was much higher in the blood of patients with DM during a COVID-19 disease. IRS-1 amounts in the blood plasma of patients with diabetes was higher than normal values. The level of IRS-1 in the blood plasma of patients with COVID-19 was much higher than in the blood of healthy people and patients with diabetes. The level of IRS-1 in the blood plasma may be one of the promising markers of COVID-19.

Keywords: 5'AMP-activated protein kinase α1, insulin receptor substrate-1, COVID-19, diabetes mellitus.

AMPK (5'AMP-activated protein kinase) is a heterotrimer consisting of a catalytic subunit (α) and two regulatory subunits (β and γ). The γ -subunit contains four potential sites that bind adenine nucleotides [1, 2]. The α subunit has 2 isoforms, α 1 and α 2 [3]. AMPK α 1 and α 2 are encoded by different genes and co-expressed in most tissues to regulate energy metabolism.

Цитування: Tronko M.D., Pushkarev V.V., Sokolova L.K., Cherviakova S.A., Belchina Y.B., Kovzun O.I., Guda B.B., Pushkarev V.M. Effects of COVID-19 and diabetes mellitus on AMPKα1 and IRS-1 amount in the blood plasma of patients. *Dopov. nac. akad. nauk Ukr.* 2022. № 3. C. 87—91. https://doi.org/10.15407/dopovidi2022.03.087

With energetic stress in the cell and an increase in the AMP concentration, ATP is replaced in the exchange centers with AMP, resulting in the allosteric activation of AMPK via phosphorylation of the 172 threonine of the α subunit by the LKB1 (liver kinase B1) complex in response to changes in cell energy, or CAMKK β (calcium-/calmodulin-dependent kinase β), which is activated by intracellular Ca²⁺ [4].

AMPK controls the energy balance of the cell. By direct phosphorylation of metabolic enzymes and transcription factors, AMPK stimulates catabolic processes — absorption of glucose, fatty acids, and their conversion via mitochondrial oxidation and glycolysis. In addition, AMPK suppresses anabolic processes — the synthesis of glucose, glycogen, and lipids in liver [5]. With type 2 diabetes and obesity, its activity decreases, and the activity of protein kinases mTORC1/p70S6K (mammalian target of rapamycin complex 1/ribosomal protein S6 kinase beta-1) increases, leading to phosphorylation of insulin receptor substrate-1 (IRS-1) and insulin resistance [6]. The effect of hypoglycemic drugs, such as metformin, is associated with the activation of AMPK [7].

Insulin receptor substrate is a key adapter protein mediating effects of insulin and insulinlike growth factors (IGF) in cells [8]. The PTB (phosphotyrosine binding) and PH (pleckstrin homology) domains are involved in the interaction of the receptor with the IRS. Phosphorylated IRS are a platform for the propagation of insulin signals in the cell, which it shares with other receptor tyrosine kinases, such as IGF-1R. IRS-1 is a member of the insulin receptor substrate family, which is also associated with tumor initiation and progression [9]. Overexpression of IRS-1 promotes the growth of cells, reduces oxidative stress-induced autophagy, and diminishes oxidative stress-mediated autophagy-dependent cell death [10, 11].

Materials and Methods. The study was conducted in the Diabetology department of the Institute. The study protocol was approved by the Institute's ethics committee. All patients signed informed consent to conduct further diagnostic and research studies.

Blood was obtained via standard venipuncture and stored in EDTA-coated vacutainer tubes. Plasma was separated via centrifugation within 10 min after blood sampling. The samples were

Plasma AMPKα and IRS-1 levels	of patients with	i diabetes and	1 COVID-19
-------------------------------	------------------	----------------	------------

Groups	AMPKα, pg/ml	m ±
Control $(n = 7)$	688.06	98.09
DM (n = 60)	944.42	61.97*
DM after COVID-19 ($n = 8$)	1310.00	118.69** +
DM + COVID-19 (n = 21)	1824.8	190.5** +
Groups	IRS-1, ng/ml	$m\pm$
Control $(n = 7)$	0.092	0.01
DM (n = 60)	0.121	0.007*
DM after COVID-19 ($n = 8$)	0.16	$0.0076*^{+}$
DM + COVID-19 (n = 21)	0.414	0.029** +

Note. $M \pm m$. Differences from control are significant: *P < 0.05; **P < 0.01. *Differences from previous group are significant, P < 0.05 - 0.01.

stored at -80 °C until use. AMPK α and IRS-1 were determined (n=81) using enzyme-linked immunosorbent assay (ELISA) kit (Elabscience, USA). The measurement was carried out at an optical wavelength of 450 nm on the immunoenzymatic plate analyzer Stat Fax 3200 (Awareness Technology, USA).

Glycated hemoglobin was determined using one HbA1c FS kit (DiaSys Diagnostic Systems GmbH, Germany). The measurement was carried out at an optical wavelength of 660 nm.

Statistical analysis and data presentation were performed using Origin 7.0 software. The results of the study are presented as $M \pm m$. To compare the data groups, Student's t-test was used. Values of $P \le 0.05$ were considered as significant.

Results and discussion. The blood plasma of 60 type 2 diabetes patients and 21 patients with diabetes and COVID-19 was used. As a control, we used the blood of healthy people (n=7) without concomitant diseases, representative of age. The level of Hb1Ac in diabetic patients was 9.62 ± 0.27 ; BMI $-30.69 \pm 1.06 \text{ kg/m}^2$. The fasting glucose content in the blood of patients with COVID-19 and diabetes was $9.6 \pm 0.92 \text{ mmol/l}$, at the time of discharge $-6.72 \pm 0.62 \text{ mmol/l}$. Average O_2 saturation was 87.3 ± 0.7 % that indicates a severe course of the disease.

The average level of AMPK α 1 in the blood of healthy people is 688.06 pg/ml (Table). In diabetic patients, this indicator is significantly higher. The amount of AMPK α 1 in the blood of people recovered from COVID-19 demonstrated the further growth of AMPK α 1. In patients with diabetes and COVID-19, the content of AMPK α 1 in the blood is almost 3 times higher than normal values. Thus, the level of AMPK α 1 is much higher in the blood of patients with DM during COVID-19 disease.

The data on the reason and significance of AMPK α appearance in the blood are limited. Plasma levels of AMPK α 1 were decreased in patients with Alzheimer disease [12]. Recent evidence also indicates novel roles for AMPK in the pathogenesis of cardiovascular diseases. AMPK α 2 deletion increases atherosclerosis in ApoE^{-/-} mice, probably via enhanced oxidative stress and endoplasmic reticulum stress. AMPK α 1 deficiency impairs autophagy-mediated monocyte differentiation and decreases monocyte/macrophage survival, which attenuates atherosclerosis in ApoE^{-/-} mice *in vivo* [12, 13].

The average level of IRS-1 in the blood of healthy people is below 0.1 ng/ml (see Table). In diabetic patients, this indicator is somewhat higher. The amount of IRS-1 in the blood of people recovered from COVID-19 demonstrated the further growth - 0.16 ng/ml. In patients with diabetes and COVID-19, the content of IRS-1 in the blood is more than 4 times higher than normal values. Thus, the level of IRS-1 substantially rises in patients with COVID-19. It should be noted that the amount of IRS-1 in the blood of people recovered from COVID-19 decreased rather quickly compared to patients with acute COVID-19 disease.

As can be seen from our data and the results obtained by other authors, the level of IRS in the blood of healthy people is quite low. However, for serious illnesses such as cancer, it more than doubles. A highly significant increase was found in serum IRS-1 of nasopharyngeal carcinoma compared with that of healthy individuals. It might be potential biomarkers in the diagnosis of cancer [11]. In the blood of patients with COVID-19 and concomitant diseases, the quantity of IRS-1 increased from 3.5 to more than 6 times. It is still difficult to assume what is the reason for the growth of this substrate and what is the mechanism of its appearance in blood plasma. Most likely, its source is blood cells or tumor cells in the case of cancer. The physiological roles of IRSs

are not limited to glucose metabolism and growth. It is known that, in addition to its participation in mediating the action of growth factors, IRS is involved in other signaling mechanisms that are still insufficiently studied. IRS-1 maintains vascular health, and IRS-1 and IRS-2 govern bone turnover and adipocyte differentiation [14, 15].

It should be noted that, in a patient with COVID-19 who died from cardiovascular complications, the level of IRS-1 was 15 times higher than the control. Perhaps, the amount of IRS-1 may be one of the markers of severity of disease.

Conclusions. The levels of AMPK α 1 and IRS-1 in the blood plasma of patients with COV-ID-19 were much higher than in the blood of healthy people and patients with diabetes. The levels of AMPK α 1 and especially IRS-1 may be promising markers of COVID-19.

REFERENCES

- 1. Ruderman, N. B., Carling, D., Prentki, M. & Cacicedo, J. M. (2013). AMPK, insulin resistance, and the metabolic syndrome. J. Clin. Invest., 123, No. 7, pp. 2764-2772. https://doi.org/10.1172/JCI67227
- 2. Xiao, B., Sanders, M. J., Underwood, E., Heath, R., Mayer, F. V., Carmena, D., Jing, C., Walker, P. A., Eccleston, J. F., Haire, L. F., Saiu, P., Howell, S. A., Aasland, R., Martin, S. R., Carling, D. & Gamblin, S. J. (2011). Structure of mammalian AMPK and its regulation by ADP. Nature., 472, No. 7342, pp. 230-233. https://doi.org/10.1038/nature09932
- 3. Carling, D., Mayer, F. V., Sanders, M. J. & Gamblin, S. J. (2011). AMP-activated protein kinase: Nature's energy sensor. Nat. Chem. Biol., 7, pp. 512-518. https://doi.org/10.1038/nchembio.610
- Racioppi, L. & Means, A. R. (2012). Calcium/calmodulin-dependent protein kinase kinase 2: roles in signaling and pathophysiology. J. Biol. Chem., 287, No. 38, pp. 31658-31665. https://doi.org/10.1074/jbc.R112.356485
- 5. Jeong, K. J., Kim, G. W. & Chung, S. H. (2014). AMP-activated protein kinase: An emerging target for ginseng. J. Ginseng Res., 38, No. 2, pp. 83-88. https://doi.org/10.1016/j.jgr.2013.11.014
- Saha, A. K., Xu, X. J., Balon, T. W., Brandon, A., Kraegen, E. W. & Ruderman, N. B. (2011). Insulin resistance due to nutrient excess. Is it a consequence of AMPK downregulation? Cell Cycle, 10, No. 20, pp. 3447-3451. https://doi.org/10.4161/cc.10.20.17886
- 7. Filippatos, T. D., Liberopoulos, E. N. & Elisaf, M. S. (2015). Dapagliflozin in patients with type 2 diabetes mellitus. Ther. Adv. Endocrinol. Metab., 6, No. 1, pp. 29-41. https://doi.org/10.1177/2042018814558243
- 8. Tronko, N. D., Kovzun, E. I., Pushkarev, V. V., Sokolova, L. K. & Pushkarev, V. M. (2018). Reception and intracellular mechanisms of insulin action (part 1). Endokrynologia, 23, No. 3, pp. 269-280 (in Russian).
- 9. Porter, H. A., Perry, A., Kingsley, C., Tran, N. L. & Keegan, A. D. (2013). IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors. Cancer Lett., 338, No. 2, pp. 239-248. https://doi.org/10.1016/j.canlet.2013.03.030
- 10. Sun, X., Chen, Y., Tan, J. & Qi, X. (2018). Serum IRS-1 acts as a novel biomarker for diagnosis in patients with nasopharyngeal carcinoma. Int. J. Clin. Exp. Pathol., 11, No. 7, pp. 3685-3690.
- 11. Chan, S.-H., Kikkawa, U., Matsuzaki, H., Chen, J.-H. & Chang, W.-C. (2012). Insulin receptor substrate-1 prevents autophagy-dependent cell death caused by oxidative stress in mouse NIH/3T3 cells. J. Biomed. Sci., 19, Art. 64. https://doi.org/10.1186/1423-0127-19-64
- 12. Wang, X., Zimmermann, H. R., Lockhart, S. N., Craft, S. & Ma, T. (2020). Decreased levels of blood AMPKα1 but not AMPKα2 isoform in patients with mild cognitive impairment and Alzheimer's disease: A pilot study. J. Alzheimer's Dis., 76, No. 1, pp. 217-224. https://doi.org/10.3233/JAD-191189
- 13. Zhang, M., Zhu, H., Ding, Y., Liu, Z., Cai, Z. & Zou, M.-H. (2017). AMP-activated protein kinase α1 promotes atherogenesis by increasing monocyte-to-macrophage differentiation. J. Biol. Chem., 292, No. 19, pp. 7888-7903. https://doi.org/10.1074/jbc.M117.779447
- 14. Hakuno, F., Fukushima, T., Yoneyama, Y., Kamei, H., Ozoe, A., Yoshihara, H., Yamanaka, D., Shibano, T., Sone-Yonezawa, M., Yu, B.-C., Chida, K. & Takahashi, S.-I. (2015). The novel functions of high-molecular-mass complexes containing insulin receptor substrates in mediation and modulation of insulin-like activi-

- ties: emerging concept of diverse functions by IRS-associated proteins. Front. Endocrinol., 6, Art. 73. https://doi.org/10.3389/fendo.2015.00073
- Reuveni, H., Flashner-Abramson, E., Steiner, L., Makedonski, K., Song, R., Shir, A., Herlyn, M., Bar-Eli, M. & Levitzki, A. (2013). Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res., 73, No. 14, pp. 4383-4394. https://doi.org/10.1158/0008-5472.CAN-12-3385

Received 19.04.2022

М.Д. Тронько, https://orcid.org/0000-0001-7421-0981

В.В. Пушкарьов, https://orcid.org/0000-0001-5940-5510

Л.К. Соколова, https://orcid.org/0000-0003-0011-0106

С.А. Червякова, https://orcid.org/0000-0002-6917-5736

Ю.Б. Бельчина, https://orcid.org/0000-0002-4289-8977

O.I. Ковзун, https://orcid.org/0000-0001-8164-7671

Б.Б. Гуда, https://orcid.org/0000-0002-9181-0679

В.М. Пушкарьов, https://orcid.org/0000-0003-0347-7771

ДУ "Інститут ендокринології та обміну речовин ім. В.П. Комісаренка НАМН України", Київ

E-mail: pushkarev.vm@gmail.com

ВПЛИВ COVID-19 ТА ЦУКРОВОГО ДІАБЕТУ НА КІЛЬКІСТЬ АМРКα1 І IRS-1 У ПЛАЗМІ КРОВІ ПАЦІЄНТІВ

Досліджено рівень АМРКα1 та IRS-1 у крові хворих на цукровий діабет та COVID-19 (*n* = 81). Кількість АМРКα1 та IRS-1 визначали за допомогою імуноферментного аналізу (Elabscience, США). АМРК контролює енергетичний баланс клітини, стимулює катаболічні процеси — поглинання глюкози, жирних кислот і їх перетворення шляхом мітохондріального окиснення та гліколізу. У разі цукрового діабету 2-го типу та ожиріння її активність знижується, а активність протеїнкіназ mTORC1/p70S6K підвищується, що призводить до фосфорилювання субстрату інсулінового рецептора-1 (IRS) і резистентності до інсуліну. Встановлено, що рівень АМРКα1 у крові хворих на цукровий діабет був значно вищим, ніж у крові здорових людей. У крові людей, які одужали від COVID-19, виявлено подальше зростання АМРКα1. У крові пацієнтів із цукровим діабетом під час захворювання на COVID-19 рівень АМРКα1 був значно вищим. Кількість IRS-1 у плазмі крові пацієнтів з цукровим діабетом була вищою за нормальні значення. У плазмі крові хворих на COVID-19 рівень IRS-1 був значно вищим, ніж у крові здорових людей та хворих на цукровий діабет. Рівень IRS-1 у плазмі крові може бути одним із перспективних маркерів COVID-19.

Ключові слова: 5'AMP-активована протеїнкіназа ол, субстрат інсулінового рецептора-1, COVID-19, цукровий діабет.